Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2005

Open Access 01-12-2005 | Review

Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)

Author: Cornel Pater

Published in: Trials | Issue 1/2005

Login to get access

Abstract

Despite widespread availability of a large body of evidence in the area of hypertension, the translation of that evidence into viable recommendations aimed at improving the quality of health care is very difficult, sometimes to the point of questionable acceptability and overall credibility of the guidelines advocating those recommendations.
The scientific community world-wide and especially professionals interested in the topic of hypertension are witnessing currently an unprecedented debate over the issue of appropriateness of using different drugs/drug classes for the treatment of hypertension. An endless supply of recent and less recent "drug-news", some in support of, others against the current guidelines, justifying the use of selected types of drug treatment or criticising other, are coming out in the scientific literature on an almost weekly basis. The latest of such debate (at the time of writing this paper) pertains the safety profile of ARBs vs ACE inhibitors.
To great extent, the factual situation has been fuelled by the new hypertension guidelines (different for USA, Europe, New Zeeland and UK) through, apparently small inconsistencies and conflicting messages, that might have generated substantial and perpetuating confusion among both prescribing physicians and their patients, regardless of their country of origin.
The overwhelming message conveyed by most guidelines and opinion leaders is the widespread use of diuretics as first-line agents in all patients with blood pressure above a certain cut-off level and the increasingly aggressive approach towards diagnosis and treatment of hypertension. This, apparently well-justified, logical and easily comprehensible message is unfortunately miss-obeyed by most physicians, on both parts of the Atlantic.
Amazingly, the message assumes a universal simplicity of both diagnosis and treatment of hypertension, while ignoring several hypertension-specific variables, commonly known to have high level of complexity, such as:
- accuracy of recorded blood pressure and the great inter-observer variability,
- diversity in the competency and training of diagnosing physician,
- individual patient/disease profile with highly subjective preferences,
- difficulty in reaching consensus among opinion leaders,
- pharmaceutical industry's influence, and, nonetheless,
- the large variability in the efficacy and safety of the antihypertensive drugs.
The present 2-series article attempts to identify and review possible causes that might have, at least in part, generated the current healthcare anachronism (I); to highlight the current trend to account for the uncertainties related to the fixed blood pressure cut-off point and the possible solutions to improve accuracy of diagnosis and treatment of hypertension (II).
Appendix
Available only for authorised users
Literature
1.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure – The JNC 7 Report. JAMA. 2003, 289: 2560-2572. 10.1001/jama.289.19.2560.
2.
2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension. 2003, 21: 1011-1053. 10.1097/00004872-200306000-00001.
3.
Williams B, Poulter NR, Brown MJ: The BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004, 328: 634-640. 10.1136/bmj.328.7440.634.PubMedPubMedCentral
4.
World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003, 21: 1983-1992.
5.
Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003, 290: 199-206. 10.1001/jama.290.2.199.PubMed
6.
Wolf-Maier K, Cooper RS, Banegas JR: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003, 289: 2363-2369. 10.1001/jama.289.18.2363.PubMed
7.
Dobson Abergavenny R: News extra: Blood pressure controls need to save on European health bills. BMJ. 2002, 325: 238-10.1136/bmj.325.7358.238.
8.
Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P: The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension. 2004, 44 (4): 398-404. 10.1161/01.HYP.0000142248.54761.56.PubMed
9.
Haffner SM, Ferrannini E, Hazuda HP, Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension. 1992, 20: 38-45.PubMed
10.
Greenlund KJ, Croft JB, Mensah GA: Prevalence of Heart Disease and Stroke Risk Factors in Persons With Prehypertension in the United States, 1999–2000. Arch of Intern Med. 2004, 164 (19): 2113-2118. 10.1001/archinte.164.19.2113.
11.
Russell LB, Valiyeva E, Carson JL: Effects of prehypertension on admissions and deaths. A simulation. Arch Intern Med. 2004, 164: 2119-2124. 10.1001/archinte.164.19.2119.PubMed
12.
Russel LB, Carson JL, Taylor WC, Milan E, Dey A, Jagannathan R: Modeling all-cause mortality: projections of the impact of smoking cessation based on the NHEFS. NHANES I Epidemiologic Follow-up Study. Am J Public Health. 1998, 88: 630-636.
13.
Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L: Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 1991, 83: 1194-1201.PubMed
14.
Grover SA, Paquet S, Levinton C, Coupal L, Zowall H: Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med. 1998, 158: 655-662. 10.1001/archinte.158.6.655.PubMed
15.
16.
17.
The World Health Report: Life in the 21st century: A vision for all. 1998, Geneva: WHO
18.
Puska P: Development of public policy on the prevention and control of elevated blood cholesterol. Cardiovasc Risk Factors. 1996, 6: 203-210.
19.
World Health Organization: Innovative care for chronic conditions: building blocks for action. Geneva: WHO, document No WHO/MNC/CCH/02.01. 2002
20.
Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB, Laragh JH, Psaty BM, Ruilope LM: Beyond hypertension. Toward guidelines for cardiovascular risk reduction. Am J Hypertens. 2004, 17 (11): 1068-1074. 10.1016/j.amjhyper.2004.06.017.PubMed
21.
Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M: Human blood pressure determination by sphygmomanometry. Circulation. 1993, 88: 2460-2467.PubMed
22.
McVicker JT: Blood pressure measurement – does anyone do it right?: an assessment of the reliability of the equipment in use and the measurement techniques of clinicians. J Fam Plann Reprod Health Care. 2001, 27 (4): 241-
23.
Ripoles Orti M, Martin Rioboo E, Diaz Moreno A, Murcia Simon M, Toledano Medina A, Fonseca Del Prozo FJ: Agreement in the measurement of blood pressure among different health professionals. Are mercury sphygmomanometers reliable?. Aten Primaria. 2001, 27 (4): 234-243.
24.
Carney SL, Gillies AH, Green SL, Paterson O, Taylor MS, Smith AJ: Hospital blood pressure measurement: staff and device assessment. J Qual Clin Pract. 1999, 19 (2): 95-98. 10.1046/j.1440-1762.1999.00308.x.PubMed
25.
Veiga EV, Nogueira MS, Carnio EC, Marques S, Lavrador MA, Souza LA, Lima NK, Nobre F: Assessment of the techniques of blood pressure measurement by health professionals. Arq Bras Cardiol. 2003, 80 (1): 89-93. 10.1590/S0066-782X2003000100008.PubMed
26.
Julius S, Kjeldsen SE, Weber M, for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004, 363: 2022-2031. 10.1016/S0140-6736(04)16451-9.PubMed
27.
The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihyhpertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 1981-1997. 10.1001/jama.288.16.1981.
28.
Campbell NR, McKay DW, Chockalingam A, Fodor JG: Errors in assessment of blood pressure: blood pressure measurement technique. Can J Public Health. 1994, 85 (2): S18-S21.PubMed
29.
McKay DW, Raju MK, Campbell NR: Assessment of blood pressure measurement techniques. Med Educ. 1992, 26 (3): 208-212.PubMed
30.
Feher M, Harris-St John K, Lant A: Blood pressure measurement by junior hospital doctors – a gap in medical education. Health Trends. 1992, 24: 59-61.PubMed
31.
McKay DW, Campbell NRC, Parab LS, Chockalingam A, Fodor JG: Clinical assessment of blood pressure. J Hum Hypertens. 1990, 4: 639-645.PubMed
32.
Mion D, Pierin AM: How accurate are sphygmomanometers?. J Hum Hypertens. 1998, 12 (4): 245-248. 10.1038/sj.jhh.1000589.PubMed
33.
Rouse A, Marschall T: The extent and implications of sphygmomanometer calibration error in primary care. J Hum Hypertens. 2001, 15 (9): 587-591. 10.1038/sj.jhh.1001241.PubMed
34.
Ali S, Rouse A: Practice audits: reliability of sphygmomanometers and blood pressure recording bias. J Hum Hypertens. 2002, 16 (5): 359-361. 10.1038/sj.jhh.1001384.PubMed
35.
Jones DW, Frohlich ED, Grim CM, Grim CE, Taubert KA: Mercury sphygmomanometers should not be abandoned: an advisory statement from the Council for High Blood Pressure Research, American Heart Association. Hypertension. 2001, 37: 185-186.PubMed
36.
O'Brien E, Waeber B, Parati G, Staessen G, Meywers MG: Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ. 2001, 322: 531-536. 10.1136/bmj.322.7285.531.PubMedPubMedCentral
37.
38.
Canzanello VJ, Jensen PL, Schwartz GL: Are aneroid sphygmomanometers accurate in hospital and clinic setting?. Arch Intern Med. 2001, 161: 729-731. 10.1001/archinte.161.5.729.PubMed
39.
Staessen JA: Blood-pressure measuring devices: time to open Pandora's box and regulate. Hypertension. 2000, 35: 1037-PubMed
40.
Ramsey M: Blood pressure monitoring: automated oscillometric devices. J Clin Monit. 1991, 7: 56-67.PubMed
41.
O'Brien E, Pickering T, Asmar R: Working Group on Blood Pressure monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit. 2002, 7: 3-17. 10.1097/00126097-200202000-00002.PubMed
42.
Gerin W, Schwartz AR, Schwartz JE: Limitations of current validation protocols for home blood pressure monitors for individual patients. Blood Press Monit. 2002, 7: 313-318. 10.1097/00126097-200212000-00004.PubMed
43.
Schwartz AR, Haas DC, Gerin W, Pickering TG: Accurate Measurement of Blood Pressure. JAMA. 2003, 289 (21): 2792-10.1001/jama.289.21.2792-a.PubMed
44.
Jones DW, Appel LJ, Sheps SG, Roccella EJ, Lenfant C: Measuring Blood Pressure Accurately: New and Persistent Challenges. JAMA. 2003, 289 (8): 1027-1030. 10.1001/jama.289.8.1027.PubMed
45.
Pickering TG, Pieper C, Chechter CB: Ambulatory monitoring and blood pressure variability. 1991, London: Science Press, 2.1-2.16.
46.
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997, 157: 2413-2446. 10.1001/archinte.157.21.2413.
47.
48.
Pickering T, for an American Society of Hypertension Ad Hoc Panel: Recommendations for use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens. 1996, 9: 1-11. 10.1016/0895-7061(95)00341-X.PubMed
49.
O'Brien E, Coats A, Owens P: Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ. 2000, 320: 1128-1134. 10.1136/bmj.320.7242.1128.PubMedPubMedCentral
50.
Mancia G, Zanchetti A, Agabiti-Rosei E: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. AMPLE Study Group. Study on ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997, 95: 1464-70.PubMed
51.
Gardner SF, Schneider EF: 24-hour ambulatory blood pressure monitoring in primary care. J Am Board Pract. 2001, 14 (3): 166-171.
52.
Schlechter CB: Sequential analysis in a Bayesian model of diastolic blood pressure measurement. Med Decis Making. 1988, 8: 191-196.
53.
Chatellier G, Day M, Dobrie G, Menard J: Feasibility study of N-of-1 trials with blood pressure self-monitoring in hypertension. Hypertension. 1995, 25: 294-301.PubMed
54.
Reeves RA: A review of the stability of ambulatory blood pressure: implications for diagnosis of hypertension. Clin Invest Med. 1991, 14: 251-255.PubMed
55.
National High Blood Pressure Education Program: Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990, 163: 1689-1712.
56.
Reeves RA: Does this patient have hypertension? How to measure blood pressure. JAMA. 1995, 273: 1211-1218. 10.1001/jama.273.15.1211.PubMed
57.
Birkett NJ: The effect of alternative criteria for hypertension on estimates of prevalence and control. J Hypertens. 1997, 15: 237-244. 10.1097/00004872-199715030-00004.PubMed
58.
O'Brian E: Ambulatory blood pressure monitoring in the management of hypertension. Heart. 2003, 89: 571-576. 10.1136/heart.89.5.571.
59.
MacDonald MB, Laing GP, Wilson MP, Wilson TW: Prevalence and predictors of white-coat response in patients with treated hypertension. Can Med Assoc J. 1999, 161: 265-269.
60.
William BW: Ambulatory blood-pressure monitoring in clinical practice. New Engl J Med. 2003, 348 (24): 2377-2378. 10.1056/NEJMp030057.
61.
Little P, Barnet J, Barnsley L, Marjoram J, Fitzgerald-Baron A, Mant D: Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood pressure. BMJ. 2002, 325: 254-259. 10.1136/bmj.325.7358.254.PubMedPubMedCentral
62.
Bellomo G, Narducci PL, Rondoni F, Pastorelli G, Stagnoni G: Prognostic value of 24-hour blood pressure in pregnancy. JAMA. 1999, 282: 1447-1452. 10.1001/jama.282.15.1447.PubMed
63.
Staessen JA, Fagard R, Thjis L: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997, 350: 757-764. 10.1016/S0140-6736(97)05381-6.PubMed
64.
Clement DL, De Buyzere ML, De Baquer DA, de Leeuw PW, Duprez DA, Fagard RH, Cheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. New Engl J Med. 2003, 348: 2407-2415. 10.1056/NEJMoa022273.PubMed
65.
Pickering T, Davidson K, Gerin W: Masked hypertension. Hypertension. 2002, 40: 795-796. 10.1161/01.HYP.0000038733.08436.98.PubMed
66.
Guillaume B, Chatellier G, Genes N, Vaur L, Vaisse B, Menard J, Mallion JM: Cardiovascular prognosis of "Masked Hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004, 291: 1342-1349. 10.1001/jama.291.11.1342.
67.
Kottke TE, Stroebel R, Hoffman R: JNC 7 – It's more than high blood pressure. JAMA. 2003, 289 (19): 2573-2575. 10.1001/jama.289.19.2573.PubMed
68.
Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002, 20: 1461-1464. 10.1097/00004872-200208000-00001.PubMed
69.
Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360: 1903-1913. 10.1016/S0140-6736(02)11911-8.
70.
PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001, 358: 1033-1041. 10.1016/S0140-6736(01)06178-5.
71.
Law MR, Wald NJ: Risk factor thresholds: their existence under scrutiny. BMJ. 2002, 324: 1570-1576. 10.1136/bmj.324.7353.1570.PubMedPubMedCentral
72.
Hansson I, Zanchetti A, Carruthers SG, Dahloef B, Elmfeldt D, Julius S: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.PubMed
73.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ. 1998, 317: 703-713.PubMedCentral
74.
Stergiou GS, Karotsis AK, Symeonidis A, Vassilopulou VA: Aggressive blood pressure control in general practice (ABC-GP) study: can the new targets be reached?. J Hum Hypertens. 2003, 17: 767-773. 10.1038/sj.jhh.1001610.PubMed
75.
McMahon S, Peto R, Cutler J: Blood pressure, stroke, and coronary heart disease. Part 1: prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990, 335: 765-774. 10.1016/0140-6736(90)90878-9.
76.
SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension: final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA. 1991, 265: 3255-3264. 10.1001/jama.265.24.3255.
77.
Mancia G, Grassi G: Rationale for the use of a fixed combination in the treatment of hypertension. Eur Heart J. 1999, 1 (Suppl L): L14-L19.
78.
79.
Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002, 20: 1461-1464. 10.1097/00004872-200208000-00001.PubMed
80.
Hoes A, Grobbee D, Lubsen J: Does drug treatment improve survival?. J Hypertens. 1995, 3: 805-811.
81.
Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C: Hypertension in the elderly: implications and generalizability of randomized trials. JAMA. 1994, 272: 1932-1938. 10.1001/jama.272.24.1932.PubMed
82.
Swales J: Pharmacological management of hypertension. Lancet. 1994, 344: 380-385. 10.1016/S0140-6736(94)91405-2.PubMed
83.
Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J: Influence of context effects on health outcomes: a systematic review. Lancet. 2001, 357: 757-762. 10.1016/S0140-6736(00)04169-6.PubMed
84.
Kleijnen J, de Craen AJM, van Everdingen J, Krol L: Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet. 1994, 344: 1347-1349. 10.1016/S0140-6736(94)90699-8.PubMed
85.
Kaptchuk TJ: Powerful placebo: the dark side of the randomized controlled trial. Lancet. 1998, 351: 1722-1725. 10.1016/S0140-6736(97)10111-8.PubMed
86.
Onel E, Hammond C, Wasson JH: An assessment of the feasibility and impact of shared decision making in prostate cancer. Urology. 1998, 51: 63-66. 10.1016/S0090-4295(97)00494-9.PubMed
87.
Benson J, Britten N: Patients decisions about whether or not to take antihypertensive drugs: qualitative study. BMJ. 2002, 325: 873-876. 10.1136/bmj.325.7369.873.PubMedPubMedCentral
88.
Redelmeier DA, Rozin P, Kahneman D: Understanding patients' decisions. JAMA. 1993, 270: 72-76. 10.1001/jama.270.1.72.PubMed
89.
Feldman R, Bacher M, Campbell N: Adherence to pharmacologic management of hypertension. Can J Public Health. 1998, 89: I16-I18.PubMed
90.
Alderman MH, Madhavan S, Cohen H: Antihypertensive drug therapy: the effect of JNC criteria on prescribing patterns and patient status through the first year. Am J Hypertens. 1996, 9: 413-418. 10.1016/0895-7061(95)00438-6.PubMed
91.
Tomlinson B: Optimal dosage of ACE inhibitors in older patients. Drugs Aging. 1996, 9: 262-273.PubMed
92.
Flack JM, Novikov SV, Ferrario CM: Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. 1996, 17 (suppl A): 16-20.PubMed
93.
Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998, 279: 1200-1205. 10.1001/jama.279.15.1200.PubMed
94.
Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW: Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. 1993, New York, NY:McGraw-Hill Co, 33-3
95.
Heerdink ER, Urquhart J, Leufkens HG: Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf. 2002, 11 (6): 447-453. 10.1002/pds.745.PubMed
96.
Cross J, Lee H, Westelinck H: Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–19999. Pharmacoepidemiol Drug Saf. 2002, 11 (6): 439-446. 10.1002/pds.744.PubMed
97.
Struijker Boudier HA: A drug is not a drug: a commentary. Pharmacoepidemiol Drug Saf. 2002, 11 (6): 437-438. 10.1002/pds.767.PubMed
98.
Cohen JS: Adverse drug effects, compliance, and initial doses of antihypertensive recommended by the Joint National Committee vs the Physicians' Desk Reference. Arch Int Med. 2001, 161 (6): 880-885. 10.1001/archinte.161.6.880.
99.
Cohen JS, Insel PA: The Physicians' Desk Reference : problems and possible improvements. Arch Intern Med. 1996, 156: 1375-1380. 10.1001/archinte.156.13.1375.PubMed
100.
Brawn LA, Castleden CM: Adverse drug reactions: an overview of special considerations in the management of the elderly patient. Drug Safety. 1990, 5: 421-435.PubMed
101.
Rochon PA, Anderson GM, Tu JV: Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc. 1999, 47: 954-959.PubMed
102.
Tomlinson B: Optimal dosage of ACE inhibitors in older patients. Drugs Aging. 1996, 9: 262-273.PubMed
103.
Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ. 1994, 308: 367-372.PubMedPubMedCentral
104.
Law MR, Wald NJ, Morris JK, Jordon RE: Blood pressure lowering drugs: analysis of 354 randomised trials to assess the value of low dose combination therapy. BMJ. 2003, 326: 1419-10.1136/bmj.326.7404.1419.PubMedPubMedCentral
105.
Sacks FM, Tonkin AM, Shepherd J: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors-the prospective pravastatin pooling project. Circulation. 2000, 102: 1893-1900.PubMed
106.
National Committee for Quality Assurance: HEDIS 2000: Technical Specifications. Washington, DC: National Committee for Quality Assurance. 1999, 2:
107.
Mulrow PJ: Hypertension: a worldwide epidemic. Hypertension primer: the essentials of high blood pressure. Edited by: Izzo JL, Black HR, Goodfriend TL. 1999, Baltimore: Williams and Wilkins, 721-723. 2
108.
Hyman DJ, Pavlik VN: Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000, 160 (15): 2281-2286. 10.1001/archinte.160.15.2281.PubMed
109.
Campbell NC: Treating hypertension with guidelines in general practice. Patients decide how low they go, not targets. BMJ. 2004, 329: 523-524. 10.1136/bmj.329.7465.523.PubMedPubMedCentral
110.
111.
112.
McAlister FA, Laupacis A: Towards a better yardstick: the choice of treatment thresholds in hypertension. Can J Cardiol. 1998, 14: 47-51.PubMed
113.
Grover SA, Paquet S, Levington C, Coupa L, Zowal H: Estimating the benefits of modifying cardiovascular risk factor: a comparison of primary versus secondary prevention. Arch Intern Med. 1998, 158: 655-662. 10.1001/archinte.158.6.655.PubMed
114.
Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J: Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomised, controlled trials. The INDANA Investigators. Ann Intern Med. 1997, 126: 761-767.PubMed
115.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421.
116.
Sever PS, Dahlof B, Poulter NR: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003, 361: 1149-1158. 10.1016/S0140-6736(03)12948-0.PubMed
117.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002, 288: 2998-3007. 10.1001/jama.288.23.2998.
118.
Misselbrook D, Armstrong D: Thinking about risk: Can doctors and patients talk the same language?. Fam Pract. 2002, 19: 1-2. 10.1093/fampra/19.1.1.PubMed
119.
Gigerenzer G, Edwards A: Simple tools for understanding risks: from innumeracy to insight. BMJ. 2003, 327: 741-744. 10.1136/bmj.327.7417.741.PubMedPubMedCentral
120.
Boulware LE, Daumit GL, Frick KD: An evidence-based review of patient-centered bahavioral interventions for hypertension. Am J Prev Med. 2001, 21: 221-232. 10.1016/S0749-3797(01)00356-7.PubMed
121.
Hlatk M: Patient preferences and clinical guidelines. JAMA. 1995, 273: 1219-1220. 10.1001/jama.273.15.1219.
122.
Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS: Clinical Inertia. Ann Int Med. 2001, 135 (9): 825-834.PubMed
123.
MacMahon S, Peto R, Cutler J: Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990, 335: 765-774. 10.1016/0140-6736(90)90878-9.PubMed
124.
Perry HMJ, Miller JP: Difficulties in diagnosing hypertension: implications and alternatives. J Hypertens. 1992, 10: 887-896.PubMed
125.
Fedder DO, Koro CE, L'Italien GJ: New National Cholesterol Education Program III guidelines for primary prevention lipid lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002, 105: 152-156. 10.1161/hc0202.101971.PubMed
126.
Graves JW, Sheps SG: Does evidence-based medicine suggest that physicians should not be measuring blood pressure in the hypertensive patient?. Am J Hypertens. 2004, 17 (4): 354-360. 10.1016/j.amjhyper.2003.12.007.PubMed
127.
Drevenhorn E, Hakansoon A, Petersson K: Blood pressure measurement: an observational study of 21 public health nurses. J Clin Nursing. 2001, 10: 189-194. 10.1046/j.1365-2702.2001.00481.x.
128.
Pickering GT, Hall GJ, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccela ED: Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Part 1: Blood Pressure Measurements in Humans: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. Published online before print December 20, 2004., [http://​hyper.​ahajournals.​org/​cgi/​content/​full/​45/​1/​142]
129.
Adams C, Burke V, Beilin LJ: Accuracy of blood pressure measurement and anthropometry among volunteer observers in a large community survey. J Clin Epidemiol. 2002, 55: 338-344. 10.1016/S0895-4356(01)00492-9.PubMed
130.
Stahl SM, Kelley CR, Neill PJ, Grim CE, Mamlin J: Effects of home blood pressure measurement on long-term BP control. Am J Public Health. 1984, 74: 704-709.PubMedPubMedCentral
131.
Edmonds D, Foerster E, Groth H, Greminger P, Siegenthaler W, Vetter W: Does self-measurement of blood pressure improve patient compliance in hypertension?. J Hypertens Supp. 1985, 3: S31-S34.
132.
Stergiou G, Megden T, Padfield PL, Parati G, O'Brien E: Working Group on Blood Pressure monitoring of the European Society of Hypertension. Self monitoring of blood pressure at home. BMJ. 2004, 329: 870-871. 10.1136/bmj.329.7471.870.PubMedPubMedCentral
133.
Horne R, Weinman J: Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic illness. J Psychosom Res. 1999, 47: 555-567. 10.1016/S0022-3999(99)00057-4.PubMed
134.
Mengden T, Hernandez Medina RM, Beltran B, Alvarez E, Kraft K, Vetter H: Reliability of reporting self-measured blood pressure values by hypertensive patients. Am J Hypertens. 1998, 11: 1413-1417. 10.1016/S0895-7061(98)00241-6.PubMed
135.
Myers MG: Self-measurement of blood pressure at home: the potential for reporting bias. Blood Press Monit. 1998, 3 (suppl 1): S19-S22.
136.
O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring: European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003, 21: 821-848. 10.1097/00004872-200305000-00001.PubMed
Metadata
Title
Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)
Author
Cornel Pater
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Trials / Issue 1/2005
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1468-6708-6-6

Other articles of this Issue 1/2005

Trials 1/2005 Go to the issue

Research

Exercise training improves aerobic endurance and musculoskeletal fitness in female cardiac transplant recipients

Research

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

Review

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

Research

Presence of factors that activate platelet aggregation in mitral stenotic patients' plasma

Research

Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]

Research

Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients – the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]